RxDoctor Payments Data

Jonathan Igo

Family · San Diego, CANPI 1215476643

Payments from drug & device makers

$16,871in general payments, 2019–2025

Across 428 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verrica Pharmaceuticals Inc.$9K
  • AbbVie$1K
  • Sanofi$850
  • Johnson & Johnson$790
  • Incyte Corporation$741
  • Arcutis Biotherapeutics, Inc.$692
  • plus $4K from 15 others

What the payments were for

  • Speaking & faculty fees$7,00041%
  • Travel & lodging$1,2517%
  • Food & beverage$8,20049%
  • Education$4212%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,871 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$52,460
Medicare patients
177
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$222,305
Cosentyx Unoready PenSecukinumab18$168,470
Dupixent PenDupilumab44$158,431
Taltz AutoinjectorIxekizumab17$131,566
AdbryTralokinumab-Ldrm17$63,669
Dupixent SyringeDupilumab14$50,739
OpzeluraRuxolitinib Phosphate15$29,784
ZoryveRoflumilast21$17,259
Fluorouracil103$4,722
Tacrolimus26$3,430
Ammonium Lactate150$3,157
Ketoconazole223$2,901
Betamethasone Dipropionate120$2,771
Calcipotriene18$2,617
Sulfacetamide Sodium32$2,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$531$63,66917 claims
Incyte CorporationOpzelura$741$29,78415 claims
Arcutis Biotherapeutics, Inc.Zoryve$692$17,25921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →